X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES JUBILANT LIFE SCIENCES VENUS REMEDIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -8.7 17.9 - View Chart
P/BV x 0.1 4.3 3.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
JUBILANT LIFE SCIENCES
Mar-14
VENUS REMEDIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs143187 76.4%   
Low Rs6565 99.8%   
Sales per share (Unadj.) Rs324.2364.3 89.0%  
Earnings per share (Unadj.) Rs6.46.8 93.6%  
Cash flow per share (Unadj.) Rs40.624.5 165.6%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs366.0164.9 221.9%  
Shares outstanding (eoy) m12.34159.28 7.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 92.7%   
Avg P/E ratio x16.218.4 88.1%  
P/CF ratio (eoy) x2.65.1 49.8%  
Price / Book Value ratio x0.30.8 37.2%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m1,28220,061 6.4%   
No. of employees `0000.96.2 14.6%   
Total wages/salary Rs m25111,052 2.3%   
Avg. sales/employee Rs Th4,430.19,383.0 47.2%   
Avg. wages/employee Rs Th278.01,786.9 15.6%   
Avg. net profit/employee Rs Th87.6176.3 49.7%   
INCOME DATA
Net Sales Rs m4,00058,034 6.9%  
Other income Rs m23191 11.9%   
Total revenues Rs m4,02358,224 6.9%   
Gross profit Rs m7855,786 13.6%  
Depreciation Rs m4222,812 15.0%   
Interest Rs m3443,237 10.6%   
Profit before tax Rs m42-72 -58.4%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m-37696 -5.3%   
Profit after tax Rs m791,090 7.3%  
Gross profit margin %19.610.0 196.7%  
Effective tax rate %-87.9-965.9 9.1%   
Net profit margin %2.01.9 105.2%  
BALANCE SHEET DATA
Current assets Rs m2,60629,280 8.9%   
Current liabilities Rs m1,98038,912 5.1%   
Net working cap to sales %15.6-16.6 -94.3%  
Current ratio x1.30.8 174.9%  
Inventory Days Days12884 152.1%  
Debtors Days Days4351 85.1%  
Net fixed assets Rs m5,35355,712 9.6%   
Share capital Rs m123155 79.9%   
"Free" reserves Rs m4,39320,968 20.9%   
Net worth Rs m4,51626,265 17.2%   
Long term debt Rs m1,61817,169 9.4%   
Total assets Rs m8,29188,606 9.4%  
Interest coverage x1.11.0 114.8%   
Debt to equity ratio x0.40.7 54.8%  
Sales to assets ratio x0.50.7 73.7%   
Return on assets %5.14.9 104.4%  
Return on equity %1.84.2 42.2%  
Return on capital %6.311.6 54.4%  
Exports to sales %037.8 0.0%   
Imports to sales %18.416.5 111.6%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs m7369,567 7.7%   
Fx inflow Rs m022,004 0.0%   
Fx outflow Rs m73611,749 6.3%   
Net fx Rs m-73610,255 -7.2%   
CASH FLOW
From Operations Rs m9978,026 12.4%  
From Investments Rs m-461-1,744 26.4%  
From Financial Activity Rs m-571-4,447 12.8%  
Net Cashflow Rs m-351,834 -1.9%  

Share Holding

Indian Promoters % 32.9 45.6 72.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.2 8.7 2.1%  
FIIs % 0.6 21.2 2.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.1 314.7%  
Shareholders   20,121 23,815 84.5%  
Pledged promoter(s) holding % 36.4 15.9 229.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 25, 2018 03:21 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS